Resources Repository
-
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Policy/Regulation | Global -
ArticlePublication 2018Resource Allocation in Decision Support Frameworks
Multi-criteria decision-making frameworks expand on typical decision analyses (cost-effectiveness and cost-benefit) by explicitly incorporating value …
Multi-criteria decision-making frameworks expand on typical decision analyses (cost-effectiveness and cost-benefit) by explicitly incorporating value tradeoffs from decision makers and summarizing the performance of investment options. This is done across all chosen dimensions of value, based on the weights provided by the decision makers, but comes at a cost. Currently there is no widely accepted method to suggest how to determine a budget constraint using multi-attribute models or to measure willingness to pay for incremental…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Health Systems | Global -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Cost-Effectiveness Analysis | Decision Analysis | Health/Medicine | Microsimulation | Infectious Diseases | Chronic Disease/Risk | North America -
ArticlePublication 2017Estimating the Fitness Cost and Benefit of Cefixime Resistance in Neisseria Gonorrhoeae
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more …
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more than half of annual infections occur in men who have sex with men (MSM). As the bacterium has developed resistance to each first-line antibiotic in turn, an improved understanding is needed of fitness benefits and costs of antibiotic resistance to inform control policy and planning. The authors developed a stochastic compartmental model representing the natural history and transmission of cefixime-sensitive…
Decision Analysis | Government/Law | Health/Medicine | Dynamic Transmission | Risk Analysis | Infectious Diseases | Health Systems | Policy/Regulation | Science/Technology | Global -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Cost-Effectiveness Analysis | Government/Law | Health/Medicine | Priority Setting/Ethics | Costing Methods | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Science/Technology | Global -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Benefit-Cost Analysis | Government/Law | Health/Medicine | Costing Methods | Chronic Disease/Risk | Policy/Regulation | North America -
ArticlePublication 2016Economic Evaluation: Bibliometric Analysis of Recent Literature
This bibliometric analysis focuses on recently published full economic evaluations of health interventions and reflects …
This bibliometric analysis focuses on recently published full economic evaluations of health interventions and reflects critically on the implications of the findings. The authors created a database drawing on 14 health, economic, and/or general literature databases for articles published between 1 January 2012 and 3 May 2014 and identified 2844 economic evaluations. They examined the distribution of publications between countries, regions, and health areas studied and compared the relative volume of research with disease burden.…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Health Systems | Economics/Finance | Science/Technology | Global -
ArticlePublication 2017Cost-Effectiveness of a Policy Strategy to Decrease Sodium Intake: Global Analysis
The objective of this study was to assess the cost effectiveness of a government policy combining …
The objective of this study was to assess the cost effectiveness of a government policy combining targeted industry agreements and public education to reduce sodium intake in 183 countries worldwide. To account for heterogeneity in efficacy across countries, a range of scenarios were evaluated, including 10%, 30%, 0.5 g/day, and 1.5 g/day sodium reductions achieved over 10 years. Country specific costs of a sodium reduction policy were estimated using the WHO Noncommunicable Disease Costing Tool. Country…
Cost-Effectiveness Analysis | Government/Law | Health/Medicine | Child/Nutrition | Chronic Disease/Risk | Social Determinants | Policy/Regulation | Food/Agriculture | Global -
DataWeb Portal 2024Medical Expenditure Panel Survey (MEPS)
The Medical Expenditure Panel Survey (MEPS) is the only national data source in the U.S. measuring …
The Medical Expenditure Panel Survey (MEPS) is the only national data source in the U.S. measuring how Americans use and pay for medical care, health insurance, and out-of-pocket spending. Annual surveys of individuals and families, as well as their health care providers, provide data on health status, the use of medical services, charges, insurance coverage, and satisfaction with care. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form…
Cost-Effectiveness Analysis | Government/Law | Health/Medicine | Costing Methods | Health Outcomes | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | North America